News

Exelixis (NASDAQ: EXEL) is not exactly a household name in the biotech industry, but that hasn't stopped the company from crushing the market this year -- rising over 30%. Perhaps one key reason

Healthcare ranks as one of the top expenses for many retirees. And it's about to become even more expensive.

Last week, the Centers for Medicare and Medicaid Services (CMS) announced the amounts of

Shares of Revolution Medicines (NASDAQ: RVMD) were up more than 20% as of 2 p.m. ET after the company announced positive phase 1/1b trial data for two cancer therapies. The clinical-stage biotech's

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

Bristol Myers Squibb (NYSE: BMY) has historically been a growth machine, always on the hunt for acquisitions and ways to get bigger and better. But acquisitions have also been a bit of a necessity

Shares of Insulet (NASDAQ: PODD) were down 12.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed last week at $145.51

Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) were up more than 15% as of 11 a.m. on Tuesday after Express Scripts said it will give certain clients access to Lexicon's drug Inpefa. The healthcar

Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.

Tango is a clinical-stage biotech that focuses on

Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food and Drug Administration (FDA) authorized marketing efforts

If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) were down more than 9% on Wednesday, after falling as much as 12% earlier in the day. The company's shares fell following a short-seller report on

When a company that's increased its dividend annually since its initial public offering announces that it's planning to cut the payment, you know something big is going on. That's exactly what's